English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NA /

CDA024-2021

Phase 1b/2, Open-Label Dose Escalation With Expansion Study Of A ACTIVE Investigational Product In Adult Subjects With Relapsed/Refractory Primary Or Secondary Central Nervous System Lymphoma, Followed By A Phase 2 Open-Label Single Dose Level Study Of The Study Drug In Adult Subjects With Relapsed/Refractory Primary Central Nervous System Lymphoma.

DISEASE GROUP:
Neuro-Oncology
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: